Trial site
Budapesti Bajcsy-Zsilinszky Korhaz Es Rendelointezet
Budapest, 1106, HungaryEU-13 widening countryNot linked to an institution yet
- 20running trials
- 8closed trials
The trials here
What the 29 trials at this site are about, from their registry records.
- Phase
- Phase 318 trials
- Phase 25 trials
- Phase 2/35 trials
- Phase 41 trial
- Status
- Active, not recruiting9 trials
- Recruiting9 trials
- Completed8 trials
- Not yet recruiting2 trials
- Suspended1 trial
- Lead sponsor
- Bayer2 trials
- Biohaven Therapeutics Ltd.2 trials
- Boehringer Ingelheim2 trials
- Merck Sharp & Dohme LLC2 trials
- Novartis Pharma AG2 trials
- and 18 more
Running trials
Not yet recruiting
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
2026-526648-11-00· Phase 2/3· Shenzhen Oculgen Biomedical Technology Co. Ltd.· Source
Recruiting
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
NCT07705555· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
2025-523938-10-00· Phase 3· Eyepoint Inc.· Source
Recruiting
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00· Phase 3· Novartis Pharma AG· Source
Recruiting
Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema
2025-522231-34-00· Phase 3· Alvotech Swiss AG· Source
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574· Phase 2· Hoffmann-La Roche· Source
Active, not recruiting
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
2025-521349-25-00· Phase 3· 4d Molecular Therapeutics Inc.· Source
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445· Phase 2· ONL Therapeutics· Source
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
2024-516654-22-00· Phase 3· Amgen Inc.· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839· Phase 2· Boehringer Ingelheim· Source
Active, not recruiting
A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Active, not recruiting
A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)
2024-510944-30-00· Phase 2/3· Eyebiotech Limited· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· Phase 3· Annexon, Inc.· Source
Enrolling by invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source
Recruiting
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
NCT05065216· Phase 2/3· DiaMedica Therapeutics Inc· Source
Active, not recruiting
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source
Active, not recruiting
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
NCT03924895· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS
2023-507906-15-00· Phase 3· Novartis Pharma AG· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error